The 36-month beta value for XRTX is at 0.85. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for XRTX is 3.65M, and currently, shorts hold a 0.93% of that float. The average trading volume for XRTX on April 23, 2025 was 41.53K shares.
XRTX) stock’s latest price update
The stock price of XORTX Therapeutics Inc (NASDAQ: XRTX) has jumped by 20.69 compared to previous close of 0.87. Despite this, the company has seen a gain of 12.90% in its stock price over the last five trading days. globenewswire.com reported 2025-04-17 that CALGARY, Alberta, April 17, 2025 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease and gout, announces receipt of notification from the Nasdaq Stock Market LLC Listing Qualifications Department that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Rule 5550(a)(2) since the closing bid price for the Company’s common shares listed on Nasdaq was below US$1.00 for 30 consecutive business days. Nasdaq Rule 5550(a)(2) requires the shares to maintain a minimum bid price of US$1.00 per share, and Nasdaq Rule 5810(c)(3)(A) provides that failure to meet such a requirement exists when the bid price of the shares is below US$1.00 for a period of 30 consecutive business days.
XRTX’s Market Performance
XORTX Therapeutics Inc (XRTX) has seen a 12.90% rise in stock performance for the week, with a 1.94% gain in the past month and a 6.59% surge in the past quarter. The volatility ratio for the week is 12.16%, and the volatility levels for the past 30 days are at 9.77% for XRTX. The simple moving average for the past 20 days is 14.57% for XRTX’s stock, with a -20.87% simple moving average for the past 200 days.
XRTX Trading at 12.17% from the 50-Day Moving Average
After a stumble in the market that brought XRTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -67.59% of loss for the given period.
Volatility was left at 9.77%, however, over the last 30 days, the volatility rate increased by 12.16%, as shares surge +6.06% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +18.14% upper at present.
During the last 5 trading sessions, XRTX rose by +12.90%, which changed the moving average for the period of 200-days by -40.34% in comparison to the 20-day moving average, which settled at $0.9165. In addition, XORTX Therapeutics Inc saw -7.05% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for XRTX
The total capital return value is set at -2.24. Equity return is now at value -83.06, with -69.30 for asset returns.
Based on XORTX Therapeutics Inc (XRTX), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -66.54.
Currently, EBITDA for the company is -4.87 million with net debt to EBITDA at 0.56. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.53.
Conclusion
In conclusion, XORTX Therapeutics Inc (XRTX) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
